Top 5 Prefered Stocks For 2014

For an investor who can invest Rs 15,000 per month, Gupta advises investing the amount into insurance, equities and gold. ��uild up a portfolio that is 60% large cap equities, 30% midcap equities and 10% gold,��she said, adding that the amount can be staggered so as to put into different funds.

Gupta�� top picks are Franklin Templeton Blue Chip in the large cap space and ICICI Pru Discovery in the midcap space. ��or gold, you can either use an ETF or a good gold fund,��she said,

Below is an edited transcript of her interview. Also watch the accompanying video.

Q: If an investor can invest Rs 15,000 per month and wants to make a crore of rupees at the end of retirement, how should he go about allocating money?

A: The good news is that you have your safe investments in place. You have some allocation to insurance. I would recommend increasing that a little bit. The existing investment will give you about Rs 20-30 lakh.

To meet the balance, you really need to have a more aggressive portfolio when you use this Rs 15000 a month. You need to build up a portfolio that is 60% large cap equities, 30% midcap equities and 10% gold. You can do this by staggering your Rs 15000 into two three funds every month.

Hot Oil Service Stocks For 2015: Bank of Ireland (BKIR)

Bank of Ireland and its subsidiaries provide a range of banking and other financial services. The Company operates in five segments: Retail Ireland, Bank of Ireland Life, Retail UK, Corporate and Treasury and Group Centre. Group Centre includes capital management activities, unallocated Group support costs and the cost of the Credit Institutions. Retail Ireland distributes a range of financial products and services through the Bank�� branch operations in the Republic of Ireland and through its direct channels. The Company operates in the life and pensions market in Ireland through its wholly owned subsidiary New Ireland Assurance Company plc (NAIC).Retail UK consists of Business Banking in Great Britain and Northern Ireland, the branch network in Northern Ireland, the United Kingdom residential mortgage business and the business activities with the United Kingdom Post Office. Corporate and Treasury division consists of Corporate Banking, Global Markets and IBI Corporate Finance. Advisors' Opinion:

• [By Sarah Jones]

  In Dublin, Bank of Ireland (BKIR) slipped 3.4 percent to 14.1 euro cents and Permanent TSB Group Holdings Plc (IPM) tumbled 13 percent to 2.6 cents. Allied Irish Banks Plc (ALBK), which is owned by the state, slid 1.5 percent to 6.5 cents.

Top 5 Prefered Stocks For 2014: Condoto Platinum NL (CPD)

Condoto Platinum NL, formerly Bailey Minerals NL, is an Australia-based mineral explorer. The Company is focused on exploring gold deposits in its Mt Palmer and Mallee Hen Point projects. Mt Palmer project consists of 21 hectares of the Mt Palmer mine covered by mining lease M77/406, which has an area of 0.21 square kilometers. The project encompasses the Mt Palmer mine within the Southern Cross district of Western Australia. The project comprises the Palmer�� Find Gold Mine. The Mallee Hen Point is an undrilled five kilometers strike gold anomaly in the Yamarna Greenstone Belt. It is located on the Cosmo Newbury Aboriginal Reserve in the Great Victoria Desert and consists of one granted exploration licence with an area of 70 square kilometers. In April 2010, the Company entered into farmin and joint venture agreements with Drake Resources Limited to explore for gold on the Mt Palmer and Mallee Hen Point projects. Advisors' Opinion:

• [By John Heinzl]

  Since April 1, the iShares S&P/TSX Canadian Preferred Share Index Fund (CPD) has dropped about 6.6%, excluding dividends. The fund is now yielding about 4.5%, up from 4.2% on April 1.

Top 5 Prefered Stocks For 2014: Bellway PLC (BWY)

Bellway p.l.c. is a United Kingdom-based holding company, owning subsidiary undertakings, which is engaged principally in housebuilding in the United Kingdom. The Company�� subsidiaries include Bellway Homes Limited, Bellway Properties Limited, Bellway (Services) Limited, Litrose Investments Limited, Bellway Financial Services Limited, Bellway Housing Trust Limited and The Victoria Dock Company Limited. Advisors' Opinion:

• [By Sofia Horta e Costa]

  Persimmon dropped 4.3 percent to 1,061 pence, while Bellway Plc (BWY) declined 3.1 percent to 1,262 pence. Bovis Homes Group Plc slipped 2.7 percent to 712 pence. Chancellor of the Exchequer George Osborne and the Bank of England will reassess the Help-to-Buy program, which allows the purchase of homes with a deposit as small as 5 percent, every September from 2014, the Treasury said.

• [By Sofia Horta e Costa]

  Bellway Plc (BWY) added 1.4 percent after the homebuilder said reservations in the past four months rose 31 percent as buyers had greater access to mortgages. Elan (ELN) Corp. jumped to a 10-month high in Dublin after Royalty Pharma increased its offer for the Irish drugmaker to as much as $6.7 billion. BT Group increased 3.7 percent as Barclays Plc recommended investors buy shares of the U.K.�� largest fixed-line company.

Top 5 Prefered Stocks For 2014: InSite Vision Inc (INSV)

InSite Vision Incorporated (InSite), incorporated in 1986, is an ophthalmic product development company advancing ophthalmic pharmaceutical products to address unmet eye care needs. The Company's current portfolio of products is based on the Company's DuraSite sustained drug delivery technology. Its DuraSite sustained drug delivery technology is a synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a drug as a solution, gel or suspension and can be customized for delivering a wide variety of drug candidates. The Company is focused its research and development and commercial support efforts on the topical products formulated with its DuraSite drug delivery technology. It may also utilize its DuraSite technology platform for the formulation of new ocular product candidates using either non drugs or compounds developed by others for non-ophthalmic indications.

AzaSite (azithromycin ophthalmic solution) 1% is a DuraSite formulation of azithromycin developed as a spectrum ocular antibiotic and approved by the United States Food and Drug Administration (FDA) to treat bacterial conjunctivitis (pink eye). Azithromycin has a spectrum of antibiotic activity and is used to treat respiratory and other infections in its oral and parenteral forms.

Besivance (besifloxacin ophthalmic suspension) 0.6% is a DuraSite formulation of besifloxacin, a spectrum ocular antibiotic approved by the FDA to treat bacterial conjunctivitis (pink eye). Besivance is the fluoroquinolone specifically developed for ophthalmic use. AzaSite Plus (ISV-502) is a fixed combination of azithromycin and dexamethasone in DuraSite for the treatment of ocular inflammation and infection (blepharitis and/or blepharoconjunctivitis).

DexaSite (ISV-305) is a DuraSite formulation of dexamethasone in development for the treatment of ocular inflammation. DexaSite is included in the Phase 3 clinical trial SPA for ! AzaSite Plus. The Company developed a topical formulation of the corticosteroid dexamethasone to treat eye inflammation caused by infections, injury, surgery or other conditions.

BromSite (ISV-303) is a DuraSite formulation of bromfenac in development for the treatment of post-operative inflammation and eye pain. ISV-101 is a DuraSite formulation with a low concentration of bromfenac for the treatment of dry eye disease.

The Company competes with Alcon Laboratories, Inc., Allergan, Inc., Bausch & Lomb, Novartis Ophthalmics, Johnson & Johnson, Merck & Co. and Pfizer.

Advisors' Opinion:

• [By CRWE]

  Today, INSV has shed (-2.74%) down -0.009 at $.320 with 15,483 shares in play thus far (ref. google finance Delayed: 10:59AM EDT June 28, 2013), but don�� let this get you down.

  InSite Vision Incorporated previously reported the company has regained North American development rights to azithromycin ophthalmic solution 2%, trademarked as AzaSite Xtra�� from Inspire Pharmaceuticals Inc., a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada. AzaSite Xtra, formulated in InSite�� DuraSite庐 topical drug delivery system, is a product candidate intended for the topical treatment of ocular infections.

• [By CRWE]

  Today, INSV surged (+7.53%) up +0.014 at $.200 with 96,500 shares in play thus far (ref. google finance Delayed: 1:12PM EDT August 15, 2013).

  InSite Vision Incorporated previously reported financial results for the quarter ended June 30, 2013. Revenues for the second quarter of 2013 were $19.2 million compared to $1.8 million for the same period in 2012. Included in the second quarter of 2013 were revenues of $15 million for the sale of the Besivance庐 royalty rights. Net income for the second quarter of 2013 was $12.1 million, or $0.09 per share, compared to a net loss of $6.8 million, or $0.05 per share, in the second quarter of 2012.